Compare
Jyong Biotech Ltd. vs Emmaus Life Sciences, Inc. vs Gain Therapeutics, Inc. vs Clene Inc.
| Latest fiscal year | Jyong Biotech Ltd. MENS | Emmaus Life Sciences, Inc. EMMA | Gain Therapeutics, Inc. GANX | Clene Inc. CLNN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $12.45M | n/a | $200.0K |
| Revenue growth (YoY) | n/a | -25.2% | n/a | -41.5% |
| Gross margin | n/a | 93.1% | n/a | 78.5% (computed) |
| Operating margin | n/a | 1.9% | n/a | n/m |
| Net margin | n/a | -60.2% | n/a | n/m |
| Net income | -$4.67M | -$7.49M | -$20.16M | -$26.17M |
| EPS (Diluted) | -$0.06 | -$0.12 | -$0.61 | n/a |
| Operating cash flow | -$3.04M | -$11.0K | -$18.47M | -$18.55M |
| Free cash flow | n/a | -$12.0K | n/a | -$18.59M |
| Cash & equivalents | n/a | $2.13M | $20.84M | $5.19M |
| Total assets | $20.78M | $21.44M | $22.82M | $18.13M |
| Total liabilities | $45.68M | $85.04M | $4.25M | $35.72M |
| Shareholders' equity | -$24.91M | -$63.61M | $18.56M | -$17.59M |
| Return on year-end equity | n/a | n/a | -108.6% | n/a |
| Shares outstanding | 76.03M | 70.19M | 42.07M | 10.85M |
Revenue, most recent five fiscal years
| Fiscal year | Jyong Biotech Ltd. | Emmaus Life Sciences, Inc. | Gain Therapeutics, Inc. | Clene Inc. |
|---|---|---|---|---|
| Latest | n/a | $12.45M Ended 2025-12-31 | $55.2K Ended 2023-12-31 | $200.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $16.65M Ended 2024-12-31 | $140.1K Ended 2022-12-31 | $342.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $29.60M Ended 2023-12-31 | $165.0K Ended 2021-12-31 | $654.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $18.39M Ended 2022-12-31 | $28.9K Ended 2020-12-31 | $473.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $20.61M Ended 2021-12-31 | n/a | $723.0K Ended 2021-12-31 |